MALT1 is a novel drug target in multiple disease areas:
- auto-immune disease (MS, Arthritis, lupus)
- allergic disease (asthma)
- lymphoma
- immunosuppression for organ transplantation
Summary of the invention
MALT1 is a paracaspase protease fine-tuning the regulation of the NFκB gene induction. MALT1 mediates cleavage of the NFκB inhibitor A20, which is a (de)ubiquitination protein.
VIB scientists have identified a peptide inhibitor of MALT1 that inhibits NFκB-induced pro-inflammatory gene-expression.
Application
MALT-Paracaspase can be used as a screening method to identify novel MALT1 inhibitors